{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:52:33Z","timestamp":1759366353970,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.revmed.2008.10.008","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T02:54:04Z","timestamp":1226372044000},"page":"S281-S285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S3","title":["Maladie de Horton et pseudopolyarthrite rhizom\u00e9lique\u00a0: nouveaut\u00e9s th\u00e9rapeutiques\u00a0? \u00c9volution et pronostic"],"prefix":"10.1016","volume":"29","author":[{"given":"P.","family":"Duhaut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2008.10.008_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","article-title":"Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study","volume":"82","author":"Hunder","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib2","first-page":"1484","article-title":"A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients","volume":"27","author":"Chevalet","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib3","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell artertitis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Maslumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1997.00210.x","article-title":"The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant cell arteritis","volume":"242","author":"Nordborg","year":"1997","journal-title":"J Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib5","first-page":"214","article-title":"Evaluation of the efficacy of etidronate therapy in preventig glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study","volume":"66","author":"Cortet","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.revmed.2008.10.008_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02529727","article-title":"A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica","volume":"58","author":"Healey","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.revmed.2008.10.008_bib7","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1007\/s00586-003-0608-x","article-title":"Medical treatment of vertebral osteoporosis","volume":"12","author":"Lippuner","year":"2003","journal-title":"Eur Spine J"},{"key":"10.1016\/j.revmed.2008.10.008_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"Van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2008.10.008_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib10","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/rheumatology\/37.4.464","article-title":"No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study","volume":"37","author":"Schaufelberger","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/03009740500474537","article-title":"No additional steroid-sparing effect of cyclosporine\u00a0A in giant cell arteritis","volume":"35","author":"Schaufelberger","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2008.10.008_bib16","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","article-title":"Treatment of longstanding active giant cell arteritis with infliximab: report of four cases","volume":"44","author":"Cantini","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","article-title":"Experience with infliximab (anti-TNF\u00e1 monoclonal antibody) as monotherapy for giant cell arteritis","volume":"62","author":"Andonopoulos","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2008.10.008_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.62.4.373","article-title":"Successful treatment of resistant giant cell arteritis with etanercept","volume":"62","author":"Tan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2008.10.008_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium- and large-vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib22","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib23","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with giant cell arteritis","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib24","first-page":"428","article-title":"\u00c9volution, traitement et pronostic de la maladie de Horton","volume":"134","author":"Barrier","year":"1983","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.revmed.2008.10.008_bib25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bmj.299.6698.549","article-title":"Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy","volume":"299","author":"Nordborg","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2008.10.008_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.0954-6820.1986.tb02778.x","article-title":"Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica","volume":"220","author":"Andersson","year":"1986","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.revmed.2008.10.008_bib27","first-page":"737","article-title":"Increased mortality due to cardiovascular disease in patients with giant cell arteritis in Northern Sweden","volume":"29","author":"Uddhammar","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib28","first-page":"1739","article-title":"The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, South Norway: a prospective study 1987\u20131994","volume":"24","author":"Gran","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0002-9343(97)89458-2","article-title":"Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort","volume":"100","author":"Matteson","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.revmed.2005.10.009","article-title":"Incidence des accidents cardiovasculaires au cours de la maladie de Horton\u00a0: r\u00e9sultats pr\u00e9liminaires de l\u2019\u00e9tude prospective en double cohorte GRACG","volume":"27","author":"Le Page","year":"2006","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2008.10.008_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard.58.6.335","article-title":"Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease","volume":"58","author":"Duhaut","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2008.10.008_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0248-8663(05)81324-4","article-title":"Les d\u00e9c\u00e8s dans la maladie de Horton. Facteurs de pronostic","volume":"13","author":"Liozon","year":"1992","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2008.10.008_bib33","first-page":"2171","article-title":"Giant cell arteritis in Lugo, Spain, is associated with low long-term mortality","volume":"24","author":"Gonzalez-Gay","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib34","first-page":"1236","article-title":"The spectrum of polymyalgia rheumatica in North-western Spain: incidence and analysis of variables associated with relapse in a ten-year study","volume":"26","author":"Gonzalez-Gay","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective follow up study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib36","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P","article-title":"Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study","volume":"41","author":"Duhaut","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/39.10.1089","article-title":"Anticardiolipin antibody levels predicts flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases","volume":"39","author":"Liozon","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2008.10.008_bib39","first-page":"S13","article-title":"Predictors of cerebrovascular accidents in giant cell arteritis in a defined population","volume":"22","author":"Pego-Reigosa","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2008.10.008_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","article-title":"Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study","volume":"122","author":"Evans","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib41","first-page":"1028","article-title":"Case records of the Massachusetts General Hospital","volume":"329","author":"Scully","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.008_bib42","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","article-title":"Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2008.10.008_bib43","first-page":"3527","article-title":"Mortality of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866308008837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866308008837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:23:10Z","timestamp":1759335790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866308008837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":43,"alternative-id":["S0248866308008837"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2008.10.008","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maladie de Horton et pseudopolyarthrite rhizom\u00e9lique\u00a0: nouveaut\u00e9s th\u00e9rapeutiques\u00a0? \u00c9volution et pronostic","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2008.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}